Clinical trials: Stool Assessment
Healthy Volunteer
Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants
The primary objective of the study is to determine whether aspirin alone or aspirin combined with various doses of rivaroxaban causes subclinical GI blood loss as determined by the HemoQuant assay.
- Trial name
- NCT05546957
- Testing
- Aspirin, rivaroxaban low dose, rivaroxaban high dose
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Pain
Investigation of Rate+Extent of Excretion of Radioactivity in Urine+Faeces After Oral Administration of [14C]AZD1386
The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD1386 in healthy male volunteers.
- Trial name
- NCT00832169
- Testing
- AZD1386
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hemorrhoids, Anal Fissures
Trial to Evaluate Effect of Lactulose on Hard Stools in Patients With Hemorrhoids or Anal Fissures
To demonstrate that lactulose acts as a stool softener, relieving the pain at defecation, improving the number of defecations and regulating the colonic transit time in patients suffering of hemorrhoids or anal fissure.
- Trial name
- NCT00160290
- Testing
- Lactulose, Plantago ovata
- Where
- 8 sites in Spain
- Volunteers
- 97 people
- Sponsor
- Solvay Pharmaceuticals
Chronic Constipation
Movicol in Childhood Constipation (ProMotion Study)
This was a single centre study comprised of two stages (Parts I and II). Part II was a 12 week randomised double blind comparison of Movicol and Lactulose Dry as maintenance therapy on an out-patient basis.
- Trial name
- NCT00404040
- Testing
- Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol), Lactulose
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Norgine
Fecal Incontinence
Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)
The purpose of this observational study is to evaluate the safety and effectiveness of the Solesta Injectable Bulking Agent in the treatment of fecal incontinence through 3 years in a real world setting.
- Trial name
- SoFI (NCT01647906)
- Where
- 20 sites in United States
- Volunteers
- 277 people
- Sponsor
- Bausch Health Americas, Inc.
Ileostomy
One Piece Drainable Pouch in Subjects With an Ileostomy
To assess the safety and performance of an enhanced one piece drainable pouch in subjects with an ileostomy.
- Trial name
- NCT01939106
- Testing
- One Piece Drainable Pouch
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- ConvaTec Inc.
Fecal Incontinence
Intra-anal Oxymetazoline in Healthy Adult Volunteers
This is a Phase 1, open-label, repeat dose, ascending dose study assessing the PK, safety, tolerability, PD, and dose- or exposure-response of Topical Oxymetazoline for intra-anal application.
- Trial name
- NCT03529487
- Testing
- Oxymetazoline
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RDD Pharma Ltd
Healthy Subjects
Effect of Litramine on Fat Excretion
The study aims to evaluate the effect of Litramine on fecal fat excretion in healthy subjects, to provide more comprehensive and robust clinical evidence in its mode of action for the treatment of obesity and weight management…
- Trial name
- NCT01590667
- Testing
- Litramine
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- InQpharm Group
Constipation
To Evaluate the Safety and Efficacy of Pediococcus Acidilactici PA53 in Relieving Constipation in Adults
To study the improvement of constipation symptoms, quality of life and mental state, intestinal function, intestinal hormones, inflammation and immunity, and intestinal flora of constipation subjects after 8-week intervention…
- Trial name
- NCT06761443
- Testing
- Probiotic, Maltodextrin
- Where
- China
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Wecare Probiotics Co., Ltd.
Infection
Safety Assessment of Lactobacillus Salivarius CECT5713 in 6 Months Old Children
The aim of the trial is to evaluate safety of a follow on formula supplemented with Lactobacillus salivarius CECT5713. A randomized double blind placebo controlled trial was carried out.
- Trial name
- P010 (NCT00724204)
- Testing
- follow on formula without probiotics, follow on formula with Lactobacillus salivarius CECT5713
- Where
- Spain
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Puleva Biotech
Healthy Volunteers
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion
The purpose of this study is to assess the relative potency of multiple oral doses of LUM001 and SHP626 administered for 7 days as assessed by fecal bile acid excretion in overweight and obese adult subjects.
- Trial name
- NCT02475317
- Testing
- Maralixibat, Volixibat
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Mirum Pharmaceuticals, Inc.
Fecal Incontinence
A Prospective, Multi-center, Randomized, Blinded Study to Evaluate Durasphere FI for the Treatment of Fecal Incontinence
The purpose of this study is to evaluate a new injectable bulking agent for the treatment of fecal incontinence in adult men and women.
- Trial name
- NCT00762047
- Testing
- Durasphere FI
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Carbon Medical Technologies
Infectious, Colitis
A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel
The xTAG Gastrointestinal Pathogen Panel (xTAG GPP) is a PCR-based assay to detect the presence or absence of gastrointestinal (GI) pathogens from human stool specimens.
- Conditions
- Infectious, Colitis, Gastroenteritis
- Trial name
- NCT01326013
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,534 people
- Sponsor
- Luminex Molecular Diagnostics
Dermatitis
A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)
The purpose of this study is to obtain information concerning the safety and effective use of a protective barrier film in patients experiencing severe incontinence associated dermatitis.
- Trial name
- NCT02724449
- Testing
- Cavilon Advanced Barrier Film
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Solventum US LLC
Fecal Incontinence
Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of 7.5, 10, 12.5 or 15 mg NRL001 in a 2 g Suppository for 14 Days
Healthy subjects will receive NRL001 or placebo once daily for 14 days. The four treatment groups, shown below, will each consist of 12 subjects: Group 1; Nine subjects will receive a dose of 7.5 mg NRL001 in a 2 g suppository…
- Trial name
- NCT01099670
- Testing
- NRL001
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Norgine
COVID-19
Observational Study on the Diagnostic Evaluation of the Intestinal Microbiota of Patients With COVID-19.
In the context of the COVID-19 pandemic, the role of the gut microbiome is yet unknown. The aim of this trial is to evaluate the clinical contribution of the gut microbiome composition and diversity on the disease severity and to…
- Trial name
- EDIFICE (NCT05107245)
- Testing
- 1test1
- Where
- 4 sites in France
- Volunteers
- 143 people
- Sponsor
- Luxia Scientific
Urinary Urge Incontinence (UUI), Urinary Frequency (UF)
Aquarius Pilot Study to Evaluate the New Axonics Trial System
Evaluation of the new Axonics External Trial System (ETS-02) in patients with overactive bladder (OAB) and/or fecal incontinence (FI).
- Conditions
- Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI), Overactive Bladder (OAB)
- Trial name
- NCT07335484
- Testing
- Axonics External Trial System (ETS)
- Where
- 5 sites in United States, Australia
- Volunteers
- 75 people
- Sponsor
- Axonics, Inc.
Feces, Impacted
Movicol in Childhood Constipation (ProMotion Study)
This was a single centre study comprised of two stages (Parts I and II). Part I was a 9-day open label evaluation of Movicol administered to patients in hospital.
- Trial name
- NCT00403858
- Testing
- Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol), Lactulose
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Norgine
Colo-rectal Cancer
Blood Collection Sub-Study for CRC Screening in Individuals 45-49 at Average Risk for CRC.
The primary objective of this sub-study, 2018-10B, is to collect blood specimens to assess new biomarkers for the detection of Colorectal Cancer (CRC).
- Trial name
- NCT03741166
- Testing
- Blood Sample Collection
- Where
- 37 sites in United States
- Volunteers
- 871 people, healthy volunteers welcome
- Sponsor
- Exact Sciences Corporation
Faecal Incontinence
A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period
The purpose of this study is to evaluate the safety, tolerability and efficacy of NRL001 in the treatment of faecal incontinence, compared against placebo
- Trial name
- NCT01656720
- Testing
- 1R, 2S-methoxamine hydrochloride
- Where
- 51 sites in Czechia, France and 7 more
- Volunteers
- 417 people
- Sponsor
- Norgine